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ABSTRACT
Objective To assess the effect of telehealthcare compared 
with usual practice in patients with chronic obstructive 
pulmonary disease (COPD).
Design A cluster-randomised trial with 26 municipal districts 
that were randomly assigned either to an intervention group 
whose members received telehealthcare in addition to usual 
practice or to a control group whose members received usual 
practice only (13 districts in each arm).
Setting Twenty-six municipal districts in the North 
Denmark Region of Denmark.
Participants Patients who fulfilled the Global Initiative for 
COPD guidelines and one of the following criteria: COPD 
Assessment Test score ≥10; or Medical Research Dyspnoea 
Council Scale ≥3; or Modified Medical Research Dyspnoea 
Council Scale ≥2; or ≥2 exacerbations during the past 12 
months.
Main outcome measures Health-related quality of life 
(HRQoL) assessed by the physical component summary (PCS) 
and mental component summary (MCS) scores of the Short 
Form 36-Item Health Survey, Version 2. Data were collected at 
baseline and at 12 month follow-up and analysed according 
to the intention-to-treat principle with complete cases, n=574 
(258 interventions; 316 controls) and imputed data, n=1225 
(578 interventions, 647 controls) using multilevel modelling.
Results In the intention-to-treat analysis (n=1225), the raw 
mean difference in PCS from baseline to 12 month follow-up 
was −2.6 (SD 12.4) in the telehealthcare group and −2.8 (SD 
11.9) in the usual practice group. The raw mean difference in 
MCS scores in the same period was −4.7 (SD 16.5) and −5.3 
(SD 15.5) for telehealthcare and usual practice, respectively. 
The adjusted mean difference in PCS and MCS between 
groups at 12 months was 0.1 (95% CI −1.4 to 1.7) and 0.4 
(95% CI −1.7 to 2.4), respectively.
Conclusions The overall sample and all subgroups 
demonstrated no statistically significant differences in 
HRQoL between telehealthcare and usual practice.
Trial registration number NCT01984840; Results.
INTRODUCTION
Chronic obstructive pulmonary disease 
(COPD) is a significant cause of impaired 
quality of life (QoL), disability, morbidity and 
mortality in industrialised countries.1 2 More-
over, it constitutes a considerable burden on 
the affected patients and places an important 
socioeconomic burden on society due to the 
growing number of patients requiring care. 
COPD and other chronic diseases challenge the 
healthcare systems in ways that call for changes 
in management and delivery of patient care.3 4
Telehealthcare has the potential to facilitate 
timely transmission of clinical and physiolog-
ical data and allows patients to be followed 
by clinicians more frequently and from a 
distance.5 It may therefore also facilitate early 
Telehealthcare for patients suffering 
from chronic obstructive pulmonary 
disease: effects on health-related 
quality of life: results from the 
Danish ‘TeleCare North’ cluster-
randomised trial
Pernille Heyckendorff Lilholt,1 Flemming Witt Udsen,2 Lars Ehlers,3 Ole K Hejlesen4 
To cite: Lilholt PH, Witt Udsen F, 
Ehlers L, et al. Telehealthcare for 
patients suffering from chronic 
obstructive pulmonary disease: 
effects on health-related 
quality of life: results from the 
Danish ‘TeleCare North’ cluster-
randomised trial. BMJ Open 
2017;7:e014587. doi:10.1136/
bmjopen-2016-014587
Received 5 October 2016
Revised 31 January 2017
Accepted 2 March 2017
1Department of Health Science 
and Technology, Aalborg 
University, Faculty of Medicine, 
Aalborg Øst, Denmark
2Danish Center for Healthcare 
Improvements, Aalborg 
University, Aalborg, Denmark
3Danish Centre for Healthcare 
Improvements, Faculty of 
Social Sciences and Faculty of 
Medicine, Aalborg University, 
Aalborg Øst, Denmark
4Faculty of Medicine, 
Department of Health Science 
and Technology, Aalborg 
University, Aalborg Øst, Denmark
Correspondence to
Dr. Pernille Heyckendorff Lilholt;  
 phl@ hst. aau. dk
Open Access Research
Strengths and limitations of this study
 ► This is the first large-scale trial in Denmark 
established to remedy the lack of international 
evidence on health-related quality of life  (HRQoL) 
in patients with chronic obstructive pulmonary 
disease (COPD) who are receiving telehealthcare.
 ► The study is a large-scale, pragmatic, two-level, 
cluster-randomised trial with 12 month follow-
up, which produces results applicable to clinical 
practice.
 ► The trial succeeded in establishing a fruitful 
intersectoral and interinstitutional cooperation 
towards a common goal; the implementation of 
telehealthcare to improve COPD patients’ HRQoL.
 ►  Short Form 36-Item Health Survey, Version 2 was 
used as a quality-of-life instrument, but may be 
less sensitive to change related to telehealthcare. It 
would have been desirable to employ a combination 
of generic and disease-specific questionnaires in 
this study.
 ► A considerable high attrition rate (651/1225 (53%) 
patients being incomplete cases or lost-to-follow-
up) was present, which could have introduced bias 
and affected the strength of the trial’s findings.
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intervention and improve clinical and patient-related 
outcomes.6 Systematic reviews conclude that there is a 
potential for demonstrating that telehealthcare improves 
health-related outcomes or is at least as good as conven-
tional treatment, but more research is needed.7–9 Some 
reviews10–12 raise concerns about the quality of the available 
evidence that is presented in heterogeneous pilot projects 
which are small, incomparable and difficult to appraise in 
relation to QoL.13–17 A recent systematic review18 indicates 
only limited evidence for a positive effect of telehealth inter-
ventions on QoL in COPD. This situation has given rise to a 
demand for large-scale studies; and a large-scale study, The 
Whole System Demonstrator Project (WSD) conducted in 
the UK, has attempted to establish a robust evidence base 
for telehealth.19–23 In the WSD, Cartwright and colleagues24 
concluded that the effect of telehealth was clinically insignif-
icant as a supplement to usual care, and telehealth did not 
improve psychological outcomes and QoL in patients with 
COPD, heart failure or diabetes.24 In a recent randomised 
controlled trial (RCT), a more extensive assessment of QoL 
and psychological outcomes was performed on the COPD 
cohort of the WSD.25 The findings from the RCT25 are 
consistent with the above conclusion made by Cartwright 
and colleagues.24 However, the RCT found no reductions 
in patients’ QoL in the longer term. In contrast, there was 
a trend towards improved QoL and mood in the telehealth 
group at longer-term follow-up, but not at the short-term 
follow-up, as observed through disease-specific measures.25
In Denmark, the lack of evidence for telehealthcare was 
discussed among healthcare decision-makers who agreed 
to strengthen the evidence base by conducting a large-
scale study as part of ‘The National Danish Action Plan 
for Dissemination of Telemedicine’.26 In 2012, the Danish 
government decided to launch the Action Plan to dissem-
inate telemedicine nationally.26 The action plan included, 
among others, the TeleCare North trial, the purpose of 
which was to contribute to the generation of valuable 
knowledge about the use of telehealthcare for patients with 
COPD in the North Denmark Region. The TeleCare North 
trial was designed based on experiences from two Danish 
pilot studies, the TeleKat Study27 28 and the Nursing Consul-
tations Study,29 30 which had both demonstrated positive 
effects of telehomecare and teleconsultations.
The present study is embedded in the Danish TeleCare 
North trial. Its objective was to assess the effectiveness 
of telehealthcare compared with usual practice based 
on an assessment of health-related QoL (HRQoL) in 
patients with COPD. It was hypothesised that adding tele-
healthcare to usual practice would significantly enhance 
patients’ HRQoL.31
METHODS
Study design
This study was conducted in accordance with the study 
protocol for the TeleCare North trial,31 which we describe 
briefly in this section. The Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT 
checklist) and the Consolidated Standards of Reporting 
Trials (CONSORT checklist) extension were followed in 
designing the TeleCare North trial (see supplementary 
material 1 and 2).
The TeleCare North trial was a large-scale, prag-
matic, two-level, cluster-randomised trial with 12 month 
follow-up. The trial was based on the collaborative efforts 
of the North Denmark Region, all municipalities in the 
Region, the Region’s general practitioners (GPs) and 
Aalborg University. The municipalities were organised 
into 26 districts with 13 clusters in each arm.
Participants
The trial targeted all patients with COPD in the North 
Denmark Region who fulfilled the inclusion criteria. All 
GPs from the Region recruited the patients with COPD 
from a list of suitable patients attending their practices. 
The selection of participants followed identical guidelines 
and instructions at all practices. All patients who accepted 
to participate and were deemed suitable for participation 
were included. The identification and recruitment of 
patients took place prior to random allocation of clusters 
in order to minimise biased recruitment. Assigned to the 
intervention or to usual practice were 1225 (578 inter-
ventions, 647 controls) patients representing different 
COPD stages, Global Initiative for COPD (GOLD I-IV).32
Inclusion and exclusion criteria
All patients with COPD who may benefit from tele-
healthcare were considered for inclusion. The following 
inclusion criteria were used: patients were required to 
have COPD as their primary disease and be diagnosed by 
spirometry, and they should receive or be motivated for 
treatment corresponding to the GOLD guidelines.32 One 
of the following criteria should also be met: a Medical 
Research Dyspnoea Council scale (MRC) score ≥3; or 
a modified Medical Research Dyspnoea Council scale 
(MMRC) score ≥2; or a COPD Assessment Test score ≥10; 
or ≥2 exacerbations during the past 12 months.
In addition, on the basis of a health professional’s qual-
ified estimate and assessment, the patients should also 
have a telephone connection, have permanent residence 
and be on the list of a GP in the North Denmark Region. 
Patients should also be able to speak Danish or they 
should be living with Danish-speaking relatives who were 
able to support them in their use of the telehealthcare 
system and to provide assistance in situations involving 
issues of comprehension of the Danish language.
Patients were excluded if they were cognitively 
impaired, had no phone line or GSM coverage, or were 
unable to understand Danish to the extent allowing them 
to complete the study questionnaires.
Intervention
The intervention of the TeleCare North trial was based 
on the concept and logic of the TeleKat study.28 Its key 
concept and primary logic was empowerment achieved 
by engaging patients with COPD in their illness and 
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increasing their coping abilities through self-monitoring. 
The study introduced extended monitoring with store-
and-forward data connected to healthcare providers to 
facilitate detection of exacerbations and rapidly initiate 
preventive antibiotic therapy.
Intervention arm: telehealthcare
Patients in the intervention group received telehealthcare 
in addition to usual practice. The telehealthcare system 
coined ‘Telekit’ was used in the TeleCare North trial. It 
consists of a Samsung Galaxy Tab2 (10.1) with associated 
devices: a digital blood pressure monitor (UA-767, plus 
BT-C, Nonin Medical, Minnesota, USA), a fingertip pulse 
oximeter (Nonin, Onyx II% SpO2) and a health preci-
sion scale (UC-321PBT-C, A&D Medical, Tokyo, Japan). 
The devices can collect and wirelessly transmit relevant 
disease-specific data consisting of answers to questions 
related to COPD exacerbations, symptoms and patients’ 
vital signs: systolic and diastolic blood pressure, heart rate, 
weight and oxygen saturation (figure 1). The patients 
were instructed to measure their vital signs, which were 
then sent asynchronously to municipality healthcare 
personnel who subsequently established if these data 
deviated from the normal threshold values. The commu-
nication between the healthcare personnel and the 
patient was one-way only. The patients were contacted if 
there were adverse changes in their values and responses. 
Patients were also contacted if the measurements were 
not carried out as agreed or the measurements were not 
received as expected.
Comparative arm: usual practice
Patients in the control group received their existing usual 
practice. This involved treatment, monitoring and care 
throughout the study period. The patients’ GPs provided 
this treatment and monitoring, and the municipali-
ties held responsibility for the practical help and care 
provided. The patients in the control group had not 
received any form of telehealthcare system; but at the 
end of the 12 month study period, they were offered the 
same Telekit system as the intervention group for ethical 
reasons.
Randomisation
On 4 November 2013, the municipality districts (n=26) 
were randomised so that patients residing in the same 
district received the same type of care—either tele-
healthcare in addition to usual practice or usual practice 
only. The municipality districts were matched 1:1 by the 
following variables: the total population size of the districts, 
the proportion of people with a higher education, the 
sum of the district’s total income, unemployment and the 
estimated number of patients with COPD.31 The districts 
were distributed randomly by a blinded volunteer with no 
relation to the trial, who performed the randomisation by 
throwing a dice. The volunteer had no knowledge of the 
distribution of districts on intervention or control group, 
respectively. The randomisation was recorded by the trial 
administration secretariat to ensure that the procedure 
was performed randomly.
Outcome measures
Upon inclusion at the GP’s office, patients were handed a 
questionnaire comprising the Short Form 36-Item Health 
Survey , Version 2 (SF-36v2)33 and questions concerning 
their baseline demographic characteristics such as gender, 
age, education, comorbidities, smoking status, marital 
status and job status. The SF-36v2 consists of 36 questions 
and is one of the most commonly used generic, vali-
dated questionnaires for measuring general HRQoL. It 
captures patients’ perceptions of physical, social, mental 
and emotional domains, and overall summary scores of 
physical component summary (PCS) and mental compo-
nent summary (MCS) are derived from domain scores 
using a norm-based scoring method.34 The scores are 
standardised to fall between 0 and 100 with a higher score 
indicating ‘better health’.33 After 12 months, a similar 
patient questionnaire was sent to the included patients to 
compare baseline data with follow-up data. The outcomes 
of this study were the patients’ mean differences in HRQoL 
at baseline and at the 12 month follow-up assessed with 
SF-36v2. The primary outcome measure was the adjusted 
mean differences in PCS summary scores between treat-
ment groups at 12 month follow-up.
Sample size
The sample size calculation was based on the study proto-
col’s31 primary outcome measure, PCS. Based on results 
from a previous Norwegian study,35 it was estimated 
that eligible patients with COPD had a mean baseline 
PCS score of 38 with an SD of 10. The average cluster 
size was assumed to be 50 with a coefficient of variation 
of 0.5. A sample size of 350 patients from at least seven 
municipality districts (clusters) in each arm (two-sided 
significance level, α=0.05, power=80%) was needed to 
detect minimal, clinically important differences (change 
equal to 5) and intracluster correlation ((ICC) equal to 
0.05) between the intervention group and the control 
group.35 The total required sample size was estimated to 
be around 800 patients with an expected lost-to-follow-up-
rate of 10%.
Figure 1 The Telekit system consists of a tablet, a blood 
pressure monitor, a fingertip pulse oximeter and a health 
precision scale.
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Statistical analysis
All analyses of the cluster-randomised trial were 
conducted according to the intention-to-treat principle. 
A post hoc subgroup analysis was also performed as 
a secondary analysis. The analyses were undertaken in 
STATA 12.1.
SF-36v2 standardised scores for each patient were 
produced using software provided by QualityMetric 
(http://www. sf- 36. org/), which converts all scores to a 
single metric (norm-based scoring) based on 2009 US 
general population norms.34 An analysis of covariance 
analysis strategy was applied.36 Two separate linear mixed 
models for continuous outcomes were used to assess PCS 
and MCS scores at 12 month follow-up controlling for treat-
ment arm, respective baseline score, age, gender, baseline 
forced expiratory volume in one second (FEV1%), marital 
status, diabetes status, cancer status and clustering at the 
municipality district level. The clusters were assumed to be 
represented as random effects, and the models had robust 
covariance structures. ICC estimates of patient-reported 
outcome variables were calculated for measurement of 
the variability within and across the clusters. The subgroup 
analyses applied the same statistical models and covariates 
as above, but with added treatment-by-covariate interaction 
for each subgroup.
Missing data were assumed missing at random and were 
handled in coordination with the health economic evalu-
ation of the same trial as described in the trial protocol31 
and followed good practices for handling missing data 
in cost-effectiveness research.37 Missing PCS and MCS 
scores and baseline characteristics were imputed using 
multiple imputation and were estimated separately by 
treatment group to allow for differential covariance 
structures in treatment group means. Imputation models 
included PCS and MCS scores, predictors for these scores 
at both time points, predictors for missing observations 
in the individual variables and all baseline characteristics. 
Continuous variables were imputed by predictive mean 
matching and categorical variables by multinominal 
logistic or logistic regression. The variables included were 
non-missing HRQoL (PCS and MCS scores), measures 
of disease status (FEV1%, forced vital capacity (FVC%)), 
diastolic and systolic blood pressure, smoking status, 
duration of COPD, potential comorbidities (diabetes, 
cardiovascular disease, mental illness, musculoskeletal 
disorders or cancer), socio-demographic variables (age, 
gender, marital status, education, employment status) 
and clustering. The imputation models involved the 
generation of 30 complete datasets combined by Rubin’s 
rule. Single imputation was performed on subjects that 
died during the 12 months by assigning their summary 
scores values of 0.38 39
The primary analysis and subgroup analysis were based 
on imputed data, but a complete case analysis was also 
included as a sensitivity analysis to check the robustness 
of the main trial findings.
RESULTS
Descriptive characteristics
The CONSORT diagram is shown in figure 2. Twenty-six 
municipal districts (13 intervention clusters; 13 control 
clusters) were randomised in 2013, and the TeleCare 
North trial was completed after the 12 month assessment 
in 2015. At baseline, 1225 (578 interventions, 647 controls) 
patients were enrolled in the TeleCare North trial. At 12 
months, 109 (18.86%) intervention patients were lost to 
follow-up (50 were dead, 59 did not respond on question-
naires) and 116 (17.93%) control patients (53 were dead, 
63 did not respond on questionnaires after baseline). In 
total, 101 (17.47%) patients in the intervention group 
and 61 (9.43%) patients in the control group withdrew 
their consent. Reasons for withdrawing from the TeleCare 
North trial included complicated technology, concomitant 
health problems, not interested, leaving local geograph-
ical area, does not trust the equipment or disappointed 
over not being a part of the telehealth intervention. None 
of the 26 clusters was lost to follow-up. At 12 months, 264 
(110 interventions, 154 controls) patients had incom-
plete data (patients that were not lost-to-follow-up but had 
missing values on items in either PCS or MCS at baseline 
or follow-up). Complete data (patients with non-missing 
values on MCS and PCS score at baseline and follow-up) 
were available for 574 (258 interventions, 316 controls) of 
the 1225 patients at 12 month follow-up, giving an attrition 
rate of 53% (figure 2).
At baseline, we assessed socio-demographic factors 
(gender, age, marital status) and health characteristics 
(smoking status, duration of COPD, FEV1%, FVC%, 
comorbidities, SF-36). Statistical comparisons of the 
participants’ baseline characteristics demonstrated that 
the two study groups were similar, except for statistically 
significant differences in FVC% (p<0.05). The control 
group’s mean FVC% (74.34%) was slightly higher than 
the intervention group’s mean FVC% (70.38%) (table 1).
Preliminary descriptive analysis of PCS and MCS scores
Table 2 presents descriptive statistics of PCS and MCS 
scores over time for the two analysis cohorts, complete 
cases (n=574) and available cases (n=1225) in each treat-
ment arm.
At follow-up, lower scores of mean PCS and MCS were 
represented in the primary analysis (n=1225) compared 
with the complete case analysis (n=574). In the primary 
analysis, the raw mean difference in PCS scores from base-
line to follow-up was −2.6 (SD 12.4) in the telehealthcare 
group and −2.8 (SD 11.9) in the usual practice group. The 
raw mean difference in MCS scores in the same period 
were −4.7 (SD 16.5) and −5.3 (SD 15.5) for telehealthcare 
and usual practice, respectively (table 2).
In the complete case analysis, the raw mean difference 
in PCS scores over time was 0.0 (SD 7.1) in the telehealth-
care group and −0.0 (SD 6.7) in the usual practice group. 
The raw difference in MCS scores was −1.5 (SD 10.6) 
and −2.0 (SD 8.7) for telehealthcare and usual practice, 
respectively. A comparison of the raw differences in PCS 
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and MCS scores between the two analysis cohorts’ indi-
cated that both complete cases and available cases scored 
lower HRQoL from baseline to follow-up, except for the 
telehealthcare group’s PCS score from the complete case 
analysis, whose score increased from baseline to follow-up 
(table 2).
 Primary analysis and complete case analysis
Adjusted outcomes
Table 3 presents adjusted mean difference in summary 
scores between treatment groups at 12 month follow-up 
for each analysis cohort.
In the primary analysis (n=1225), the adjusted mean 
differences in summary scores at 12 month follow-up were 
PCS 0.1 (95% CI −1.4 to 1.7) and MCS 0.4 (95% CI −1.7 to 
2.4). The overlapping confidence intervals indicated that 
differences between groups at 12 month follow-up were 
non-significant (table 3).
In the complete case analysis (n=574), the adjusted 
mean differences in summary scores at 12 month 
follow-up were PCS 0.2 (95% CI −0.9 to 1.3) and MCS 0.4 
(95% CI −1.0 to 1.7). The adjusted outcomes indicated 
no evidence of statistically significant differences between 
groups at 12 month follow-up (all CIs crossed 0) (table 3).
Secondary analysis
We also performed a posteriori-defined subgroup anal-
ysis, which showed no statistically significant effect of the 
intervention in any of the defined subgroups. Tables 4 and 
5 provide estimates of both adjusted mean differences in 
PCS and MCS summary scores, 95% CIs and p values for 
the total sample and for subgroups.
DISCUSSION
The present study hypothesised that adding telehealth-
care to usual practice would significantly increase 
Figure 2 CONSORT diagram of the TeleCare North trial.
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patients’ HRQoL.31 This hypothesis was rejected. We 
found no statistical QoL differences between groups in 
either the primary analysis, the complete case analysis or 
in any of the subgroups.
Interpretation of findings
Despite the non-significant differences, the mean differ-
ences in PCS and MCS scores at 12 month follow-up were 
larger for the control group than for the intervention 
group, which could indicate a faster deterioration over 
time for the controls than for the intervention patients. 
The largest mean difference was seen in MCS. If this is 
the case, it might be explained by the difficulty associ-
ated with affecting the physical QoL compared with the 
mental QoL. The slower decline in MCS for the tele-
healthcare group may be interpreted as a psychological 
benefit derived from using the Telekit.
Although the subgroup analysis indicated no statisti-
cally significant effects of the intervention in any of the 
posteriorly defined subgroups, there was an indication of 
some positive effects on HRQoL within certain subgroups 
of the intervention group compared with usual practice. 
These trends towards positive effects on HRQoL should 
be further investigated.
Strengths and weaknesses
The present study was the first Danish large-scale trial 
established to remedy the lack of international evidence 
on HRQoL in patients with COPD who are receiving 
telehealthcare. A total of 1225 participants from 26 
municipality districts in the North Denmark Region 
were included in the analysis. The trial succeeded in 
establishing a fruitful cooperation between many stake-
holders with different interests in the trial. The trial 
hence demonstrated the feasibility of intersectoral and 
interinstitutional collaboration towards a shared end, viz. 
the implementation of telehealthcare to improve COPD 
patients’ HRQoL.
In contrast to the WSD,22–25 the TeleCare North trial 
compared the effects of telehealthcare with the effects of 
usual practice in patients with COPD only. The design of 
the WSD was characterised by variability in terms of the 
employed technologies, the recruited sample, the type of 
intervention and defined care pathways. Contrary to the 
WSD,40 the TeleCare North trial used a ‘clean’ control 
group of patients with COPD who received usual practice 
and no other forms of care.
The TeleCare North trial was based on the same 
concept as in previous Danish pilot studies27–30 41 namely 
to increase patient empowerment and to detect disease 
deterioration through self-monitoring. In the present 
study, we attended to clarify the mechanisms that were 
supposed to provide effects. Organisational initiatives to 
further this concept, for example, ensuring that patients 
had functional telehealthcare equipment, instructing 
patients how to use this equipment and by gearing the 
organisation to rapidly respond to reported measures to 
prevent COPD exacerbations. That no significant effects C
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of HRQoL were found therefore cannot be attributed to 
patients’ lack of equipment, a lack of instructions or inad-
equate operational equipment.
In the trial, we found a considerable high attrition rate 
of 53% among participants with over half of the sample 
not providing follow-up data due to incomplete cases with 
missing data or loss to follow-up. Conducting a sensitivity 
analysis as a complete case analysis was therefore relevant 
in order to explore differences among complete and 
available cases. The high attrition rate may be attributed 
to disease progression and may have affected the findings 
of the trial. However, the consistency of results indicates 
that conclusions on findings are robust in spite of the 
high attrition rate. Further research is required to find 
explanations for high attrition rate among patients with 
COPD.
The subgroup analysis was not prespecified at the outset 
of the trial but was undertaken after the data collection of 
the trial. Because of the limitation noted, the findings of 
the post hoc subgroup analysis should be interpreted with 
caution irrespective of their significance.
We cannot rule out the influence of non-specific effects 
like a Hawthorne effect42 or ‘natural history effects’,43 
both of which could have influenced the intervention 
and the control group to some extent. The potential pres-
ence of any such effects may explain why differences in 
HRQoL between the groups were difficult to detect.
The baseline variables used in the TeleCare North 
trial were not exhaustive; nor were all relevant variables 
included. At baseline, the FVC% indicated that the 
patients in the intervention group were poorer than the 
patients in the control group. It is widely known that 
QoL deteriorates with increasing severity of COPD.44 
This may also contribute to explaining why no significant 
differences in HRQoL were found between the groups. 
It would have been desirable to supplement the baseline 
variables with other clinical characteristics such as the 
MRC dyspnoea score and with activities-of-daily-living 
measures to determine if the groups differed from each 
other in relation to their state of health. The number of 
selected baseline variables made it possible to classify the 
patients only according to the old GOLD classification 
(I–V). It would have been desirable to classify the patients 
according to the new GOLD classification (A–D) which 
is based on symptoms, airflow obstruction and exacerba-
tion history. Use of the new GOLD classification would 
probably have made it possible to establish more relevant 
subgroups.32
The SF-36v2 was selected as an appropriate outcome 
measure because it is a useful, generic and validated ques-
tionnaire for comparing differences between populations. 
It is possible, however, that generic questionnaires do not 
adequately measure the QoL issues that different groups 
of patients experience. It has been shown that the SF-36 
is susceptible to ceiling and floor effects as it is applicable 
to a wide population of both healthy and sick individuals. 
It is possible that the SF-36v2 was not sufficiently sensi-
tive to changes and to identifying outcome differences in 
Table 2 Descriptive analysis of physical component summary (PCS) and mental component summary (MCS) scores
Primary analysis (n=1225)† Complete case analysis (n=574)
THC UP THC UP
PCS at follow-up 34.6 (13.9) 34.7 (13.8) 38.3 (9.6) 38.1 (9.6)
MCS at follow-up 43.4 (17.2) 43.5 (17.3) 48.4 (11.2) 48.6 (11.4)
Difference in PCS scores from baseline to follow-up* −2.6 (12.4) −2.8 (11.9) 0.0 (7.1) −0.1 (6.7)
Difference in MCS scores from baseline to follow-up* −4.7 (16.5) −5.3 (15.5) −1.5 (10.6) −2.0 (8.7)
Data are mean (SD).
All data are based on norms-based scoring.
*Follow-up score minus baseline score.
†Primary analysis has imputed missing PCS and MCS scores.
 THC, telehealthcare; UP, usual practice.
Table 3 Adjusted mean difference in physical component summary (PCS) and mental component summary (MCS) scores 
between groups, 12 month follow-up
Primary analysis (n=1225)† ICC Complete case analysis (n=574) ICC
PCS (adjusted mean difference)* 0.1 (−1.4 to 1.7) 0.0 0.2 (−0.9 to 1.3) 0.0
MCS (adjusted mean difference)* 0.4 (−1.7 to 2.4) 0.0 0.4 (−1.0 to 1.7) 0.0
Data are mean (95% CI).
All data are based on norms-based scoring.
Differences can be interpreted as the observed extra effect of telehealthcare compared with usual practice when all mentioned covariates and 
clustering are taken into account.
*Adjusted mean differences are based on multilevel models controlling for all mentioned covariates and clustering.
†Primary analysis has imputed missing PCS and MCS scores.
ICC, intraclass coefficient. 
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patients with COPD.45 This was also confirmed by Rixon 
et al,25 who suggest that generic instruments are less sensi-
tive to change related to telehealth than disease-specific 
instruments are. COPD is associated with symptoms that 
might have an impact on the patients’ QoL, which makes 
it uncertain whether the generic questionnaires capture 
these aspects. Another alternative for measuring QoL 
could have been a more disease-specific questionnaire 
for patients with COPD, such as the St. George’ Respira-
tory Questionnaire46 and other QoL instruments such as 
the Chronic Respiratory Questionnaire,47 the EQ-5D48 or 
the Hospital Anxiety and Depression Scale .49 A study by 
Engström and colleagues50 illustrated that a combination 
of generic and disease-specific questionnaires was the 
Table 4 Primary outcome and subgroup analyses of the chronic obstructive pulmonary disease patients’ socio-demographic 
characteristics: adjusted mean differences in physical component summary (PCS) and mental component summary (MCS) 
scores for the total sample and subgroups, adjusted for respective baseline PCS or baseline MCS scores and age, gender, 
baseline forced expiratory volume in one second of predicted normal (FEV1), marital status, cancer and diabetes
Socio-demographic characteristics
Effectiveness
Total sample
PCS
0.1
PCS 95% CI
(−1.4 to 1.7)
Wald 
test
p value
ICC
0.0
MCS
0.4
MCS 95% CI
(−1.7 to 2.4)
Wald test
p value
ICC
0.0
Gender
  Female (54%) −0.3 (−1.6 to 1.1) 0.6 0.0 −0.5 (−2.6 to 1.7) 0.3 0.0
  Male (46%) 0.5 (−2.1 to 3.2) −1.3 (−1.9 to 4.5)
Age (years)
  <60 (16%) −0.5 (−4.0 to 3.1) 0.7 0.0 −0.1 (−4.3to 4.1) 0.9 0.0
  60–69 (33%) −1.2 (−3.2 to 0.9) −0.7 (−3.7 to 2.3)
  70–79 (38%) 1.0 (−1.9 to 3.9) 0.7 (−2.7 to 4.2)
  ≥80 (13%) 1.7 (−3.6 to 7.0) 2.2 (−5.0 to 9.3)
Marital status
  Married/relationship 
(58%)
0.3 (−1.8 to 2.4) 0.7 0.0 1.0 (−2.2 to 4.2) 0.8 0.0
  Single (23%) −0.9 (−3.8 to 2.0) −0.6 (−4.9 to 3.6)
  Widow/widower (19%) 0.9 (−2.6 to 4.3) −0.5 (−4.9 to 4.0)
Smoking status
  Non-smokers (66%) 0.4 (−1.6 to 2.5) 0.6 0.0 1.3 (−1.6 to 4.3) 0.2 0.0
  Smoker (34%) −0.4 (−2.8 to 1.9) −1.5 (−4.3 to 1.4)
Job status
  Full-time job (5%) −1.2 (−6.1 to 3.8) 0.8 0.0 6.0 (−12.6 to 0.6) 0.2 0.0
  Part-time job (7%) −0.8 (−5.0 to 3.3) 0.8 (−5.2 to 6.9)
  No job (88%) 0.3 (−1.4 to 2.0) 0.7 (−1.7 to 3.2)
Education
  Elementary school, 7th–
10th grade (48%)
0.1 (−1.6 to 1.8) 1.0 0.0 0.7 (−2.0 to 3.4) 0.7 0.0
  High school (2%) 0.6 (−7.9 to 9.0) 4.7 (−8.0 to 17.4)
  Skilled worker (34%) 0.8 (−1.8 to 3.4) 1.2 (−2.5 to 4.9)
  Short-term education 
(2–3 years) (8%)
−1.6 (−5.7 to 2.5) −2.4 (−8.1 to 3.3)
  Middle-term education 
(3–5 years) (7%)
−0.5 (−6.4 to 5.5) −4.3 (−10.2 to 1.6)
  Long-term education 
(5–8 years) (1%)
−0.8 (−18.7 to 17.1) 0.4 (−22.6 to 23.4)
All data are based on norms-based scoring.
Multilevel linear models controlling for baseline PCS or MCS score and age, gender, baseline FEV1, marital status, cancer and diabetes and 
clustering. Priori hypothesis was that adding telehealthcare to usual practice would improve patients’ health-related quality of life relative to 
usual practice.
Mean difference; 95% CIs.
ICC, intraclass coefficient.
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most suitable choice for measuring differences in COPD 
patients’ HRQoL following an intervention. They argued 
that both disease-specific effects and the overall burden 
of the disease on everyday functioning and mental well-
being should be considered. This was also confirmed in 
a review by Chen, who recommended the use of both 
generic and disease-specific questionnaires in combina-
tion.45
Another relevant consideration is whether QoL 
measures should be expected to change by implementa-
tion of telehealthcare. Two recent systematic reviews18 51 
found that the impact of telehealth on QoL in patients 
with COPD is limited. However, the review suggested that 
active interventions may improve QoL outcomes in the 
telehealth group compared with usual care.18 Based on 
this study’s results and the literature,7 18 24 25 telehealth-
care is not assumed to be convincing when looking at 
QoL as an isolated factor. However, QoL improvements 
may be expected over time25 in active telehealthcare 
interventions where some kind of self-management skills 
training is an integrated part of the intervention.18
The strategy of offering inclusion to all patients with 
COPD who may benefit from telehealthcare in the whole 
region of North Denmark strengthens the generalisability 
of the findings. So does the use of minimal inclusion 
criteria and the 12-month-long continuous assessment 
of the patients. Given the significant differences between 
COPD and other chronic diseases, the findings should, 
however, not be applied to other chronic diseases.
The North Denmark Region is fairly representative of 
the whole country of Denmark in terms of population and 
healthcare system. The findings are therefore generally 
applicable to the whole of Denmark and, at least partly, 
also to countries with similar healthcare systems such as 
the other Nordic countries.
Comparison with other studies
Our results demonstrate a further lack of any improve-
ments in QoL following implementation of telehealthcare 
in COPD. The WSD is the only large-scale study of tele-
healthcare in COPD that we have come across. The findings 
from the WSD study by Cartwright and colleagues24 
indicated no improvement in HRQoL from telehealth, 
but some significant differences suggested that the tele-
health group had a slower rate of deterioration over time 
compared with the control group.
Similarly, no statistical differences in the Telescot 
study52 or the ‘The Virtual Hospital’ trial53 were identi-
fied between the control and intervention groups. The 
results of our study are consistent with the findings from 
these studies.
The review and meta-analysis by McLean et al7 is also 
relevant to consider; in contrast, their findings indicated 
possible impact of COPD patients’ QoL. Another recent 
review by Cruz et al10 indicated inconsistency in HRQoL 
findings with most of the studies reporting no signifi-
cant changes in HRQoL. However, the studies included 
in the reviews used different HRQoL instruments; and it H
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has therefore been recommended to use similar HRQoL 
instruments in future studies to enable comparisons.7 10
Nevertheless, the benefits in relation to QoL may be 
debated although telehealthcare seems unlikely to reduce 
QoL. One of our previous findings from the TeleCare 
North trial indicated that the intervention patients expe-
rienced enhanced control, freedom, security and greater 
awareness of their COPD symptoms when using the tele-
healthcare system.54 These benefits are not underpinned 
by the present study’s findings on HRQoL.
Implications for practice
Our findings indicate that adding telehealthcare to usual 
practice does not improve HRQoL in patients with COPD. 
We did not succeed in achieving the HRQoL effects we had 
hoped for, and the reduced HRQoL in both groups means 
that it is doubtful whether telehealthcare benefits patients’ 
QoL. Therefore, policymakers and healthcare profes-
sionals should consider whether telehealthcare should be 
implemented to achieve other objectives than improving 
patients’ HRQoL, that is, saving costs, reducing mortality, 
affecting other outcome variables, and so on.
Furthermore, it is relevant to explore other domains 
such as physical activity, psychological symptoms and 
different modes of telehealth application and interven-
tions, which may be important in improving QoL. In 
addition, more research should be considered within 
more specific subgroups of patients with COPD to assess 
whether telehealthcare has a particularly beneficial effect 
on QoL in some groups. It is possible that patients’ QoL 
varies between subgroups. Knowledge of such varia-
tion is useful and may inform future implementation of 
telehealthcare allowing for targeting of specific patient 
subgroups.
Future directions
In the future, more research is needed into the underlying 
mechanisms behind this lack of an identifiable effect. More 
qualitative research is required to gain a deeper under-
standing of the mechanism and preconditions needed 
to improve patients’ HRQoL by use of telehealthcare. A 
greater effort should be dedicated to studying the specific 
subgroups instead of the population as whole because 
telehealthcare systems likely fit some patients better than 
others. Furthermore, the patients with COPD in the present 
trial were recruited from different municipalities, some of 
which might have been better at organising telehealthcare 
than others. Large-scale studies are therefore not recom-
mended until these underlying mechanisms have been 
further investigated.
Future studies should recognise telehealthcare as a 
complex intervention. Such studies should therefore be 
designed as a mix of randomised controlled trials and other 
research designs to fully assess complex interventions. It 
is possible that we have jumped too quickly to large-scale 
operational trials. Furthermore, research on the causal rela-
tionship between QoL and patients’ socio-demographic and 
health characteristics is limited, indicating that a number of 
exploratory studies need to be performed within the Tele-
Care North trial in the future.
In conclusion, the findings of the present study indicate 
that the potential of telehealthcare for improving COPD 
patients’ HRQoL is limited. However, it is assumed on the 
basis of these results that telehealthcare as an additional 
service alongside the existing clinical care does not lead to 
poorer QoL.
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